Palantir Soars Again. How High Can the AI Stock Go?
Palantir (NASDAQ: PLTR) came into its fourth-quarter earnings report with its shares priced to perfection, but the AI stock ...
1 AI Stock to Buy Before It Soars 335% to $1 Trillion, According to a Wall Street Analyst
Looking ahead, IDC estimates AI platform sales will increase at 40% annually to reach $153 billion by 2028. Palantir ...
Palantir: Ontology Gives It A Moat But Doesn't Solve Valuation Worries
Palantir's financial results support this, with very strong revenue growth and margin expansion. Learn why PLTR stock is a ...
Can Palantir Become a Trillion-Dollar Company?
Palantir no doubt delivered some impressive results in the fourth quarter and throughout 2024. In Q4, overall revenue grew 36%, with U.S. revenue up 52%, including U.S. commercial growth of 64% and ...
App Orchid Announces an Insights Accelerator for Google Cloud Cortex Framework Customers, Powered by Google’s Gemini Models
App Orchid, a Google Cloud Cortex Framework partner, will enable customers to ask natural language questions and get ...
Palantir Q4 2024 Earnings: Look Beyond The Multiples And AIP
Palantir surpasses Q4 expectations, easing market concerns about AI investment ROI and showcasing strong growth for the new ...
Palantir Shares Rose 368% And AI Could Propel Them Higher
The company’s commercial revenue increased 64% in the quarter while U.S. government sales rose 45%. But if Wall Street ...
Palantir price target raised to $105 from $47 at DA Davidson
DA Davidson analyst Gil Luria raised the firm’s price target on Palantir (PLTR) to $105 from $47 and keeps a Neutral rating on the shares. The ...
Analysts race to overhaul Palantir stock price targets after Q4 earnings
Palantir blasted Street earnings forecasts late Monday, with revenues rising 36% from the prior-year period to $827.5 million ...
FVE up to $90 From $79 as American Exceptionalism and AI Value Chain Justify Excitement
We view Palantir’s financial position as healthy and improving. As of December, Palantir had nearly $2 billion in cash and $3.1 billion in marketable securities (mostly US Treasury securities) and no ...
The Lancet4d
Pioneering a new field of computational pharmacophenomics to unlock the life-saving potential of existing medicines
All physicians are faced with the challenge of how to help patients with no approved therapies for their diseases. What are ...
Worth the Hype: Palantir’s Ontology, Switching Costs Warrant Quadrupling of Our Fair Value Estimate
We view Palantir’s financial position as healthy and improving. As of September, Palantir had nearly $800 million in cash and $3.8 billion in marketable securities (mostly US Treasury securities) and ...